• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Breakpoint tables are used together with other EUCAST guidance

The EUCAST breakpoint tables are part of a system for categorising microorganisms as susceptible (S and I) and resistant (R) to agents approved for use in the treatment of infectious diseases. Breakpoint tables are freely available but we would like to remind users of other parts of the system which…

Get to know more

Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim.

Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim - public consultation 2025-05-07 - 2025-06-18. The current breakpoints of trimethoprim-sulfamethoxazole are higher than the epidemiological cut-off values for several species. There is absence of PK/PD data for…

Get to know more

Development of Clinical Breakpoints and ECOFFs

Development of Clinical Breakpoints and ECOFFs The EUCAST AMST develops breakpoints and methods for antimicrobial susceptibility testing of mycobacteria. Rationale Documents Discover More Public Consultations A chance to review proposed EUCAST changes. Discover More Submit non-truncated MIC…

Get to know more

EUCAST Statutes

EUCAST Statutes EUCAST Statutes outlines the objectives, membership structure, consultation and decision process, breakpoint setting for new agents, meetings, publication policy, declarations of interests and funding of EUCAST. The statutes were originally published in November 1999 and have been…

Get to know more

General consultation on breakpoints for anaerobic bacteria

EUCAST general and public consultation on breakpoints for anaerobic bacteria. Theconsultation pertains to the clinical breakpoints for Bacteroides spp., Prevotella spp., Fusobacterium necrophorum, Clostridium perfringens and Cutibacterium acnes that have now been reviewed against the MIC and zone…

Get to know more

Pefloxacin screening for fluoroquinolone resistance in Enterobacterales

Fluoroquinolone breakpoints are under review. Shortly there will be a public consultation. Since industry and users sometimes complain that EUCAST fails to warn of upcoming changes we now emphasize that (a) a change is coming, (b) breakpoints will be reduced further and that (c) screening for…

Get to know more

Subcommittees

Subcommittees EUCAST subcommittees are set up to deal with specific issues or areas requiring particular expertise. Consultations and decisions on subcommittee proposals are made through the EUCAST Steering Committee and follows the structure of all other consultations and decisions. When…

Get to know more

Important Additional Information

Important Additional Information Expected phenotypes, expert rules, and detection of resistance mechanisms are important complements to susceptibility testing and should be consulted before releasing results. Expected phenotypes help with validation of identification and susceptibility tests. Expert…

Get to know more

Several public consultations - deadline 15 November 2021

There are several public consultations which will expire 15 November, 2021. Vibrio species - genral consultationon EUCAST clinical breakpoints for five species pathogenic to man(1 October - 15 November). Queries on the material can be addressed to G Kahlmeter (gunnar.kahlmeter@eucast.org)…

Get to know more

About EUCAST

About The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is a scientific committee formed in 1997. EUCAST is jointly organised by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the European Centre for Disease Prevention and Control (ECDC), and…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here